Eicosanoids as a new class of ocular hypotensive agents. 3. Prostaglandin A2-1-isopropyl ester is the most potent reported hypotensive agent on feline eyes

Add time:08/26/2019    Source:sciencedirect.com

It has been shown that prostaglandin A2 (PGA2) is a more potent ocular hypotensive agent in cats than other PG free acids. We report here that significant IOP reduction can be achieved in normotensive cat eyes with the use of even lower doses of PGA2-1-isopropyl ester (PGA2-IE) than with PGA2, PGF2α-1-isopropyl ester (PGF2α-IE), or any other known ocular hypotensive agent. Furthermore, single applications of 0·5 μg of PGA2-IE maintain significant IOP reductions for at least 24 hr. This hypotensive effect is enhanced during the first 3–5 days of daily treatment. Significant IOP reductions were maintained for several months as long as PGA2-IE was applied daily or at least once every 48 hr. None of the cats manifested signs of discomfort in response to treatment with doses ranging from 0·10 to 1·25 μg of PGA2-IE. Moreover, the extent of anterior chamber flare was less than that typically observed after the topical application of hypotensive doses of PGE2, PGD2, PGF2α, or the esters or tromethamine salt of PGF2α. Although it is possible that the human eye would respond differently to PGs of the A type, the results of these studies suggests that PGA2-IE or other esters of derived PGs of the A type, and probably the B type, may offer significant therapeutic advantages over the PGF2α tromethamine salt and PGF2α-IE, which have been shown to exert significant hypotensive effects on normal and glaucomatous human eyes.

We also recommend Trading Suppliers and Manufacturers of prostaglandin A2 isopropyl ester (cas 114084-85-4). Pls Click Website Link as below: cas 114084-85-4 suppliers

Prev:ArticlesOral Ibandronic acid (cas 114084-78-5) versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial
Next:Initial clinical studies with prostaglandins and their analogues)